thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease

被引：1
|
作者：
Benitez, J. M. [1 ]
Garcia-Sanchez, V. [1 ]
Gisbert, J. P. [2 ,3 ]
机构：
[1] Univ Cordoba, Dept Gastroenterol, Hosp Univ Reina Sofia, IMIBIC, Cordoba, Spain
[2] Hosp Univ La Princesa, Dept Gastroenterol, IIS IP, Madrid, Spain
[3] CIBEREHD, Madrid, Spain
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2015年 / 41卷 / 05期
关键词：
CROHNS-DISEASE; PREDICTIVE FACTORS; AZATHIOPRINE; EFFICACY; THERAPY; MAINTENANCE; RELAPSE;
D O I：
10.1111/apt.13066
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：494 / 495
页数：2
相关论文
共 50 条
  • [21] FORECASTED INFLIXIMAB CONCENTRATIONS DURING INDUCTION PREDICT TIME TO REMISSION AND SUSTAINED DISEASE CONTROL OF INFLAMMATORY BOWEL DISEASE
    Rabizadeh, Shervin
    D'Haens, Geert
    Dubinsky, Marla C.
    Panetta, John C.
    Everts-van der Wind, Annelie
    Dreesen, Erwin
    Spencer, Elizabeth A.
    Laharie, David
    Vermeire, Severine
    Dervieux, Thierry
    GASTROENTEROLOGY, 2023, 164 (06) : S1114 - S1114
  • [22] Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease
    Vermeire, Severine
    Dubinsky, Marla C.
    Rabizadeh, Shervin
    Panetta, John C.
    Spencer, Elisabeth A.
    Dreesen, Erwin
    D'Haens, Geert
    Dervieux, Thierry
    Laharie, David
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (06)
  • [23] The Impact of Thiopurine Hypermethylation on Clinical Outcomes in Patients With Inflammatory Bowel Disease
    Blaker, Paul A.
    Fong, Steven C.
    Smith, Melissa A.
    Kariyawasam, Viraj C.
    Marinaki, Anthony M.
    Irving, Peter M.
    Sanderson, Jeremy D.
    GASTROENTEROLOGY, 2014, 146 (05) : S246 - S246
  • [24] Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease
    Hindorf, U.
    Lindqvist, M.
    Peterson, C.
    Soderkvist, P.
    Strom, M.
    Hjortswang, H.
    Pousette, A.
    Almer, S.
    GUT, 2006, 55 (10) : 1423 - 1431
  • [25] Thiopurine treatment in inflammatory bowel disease: Response predictors, safety, and withdrawal in follow-up
    Costantino, Giuseppe
    Furfaro, Federica
    Belvedere, Alessandra
    Alibrandi, Angela
    Fries, Walter
    JOURNAL OF CROHNS & COLITIS, 2012, 6 (05): : 588 - 596
  • [26] Thiopurine pharmacogenomics and pregnancy in inflammatory bowel disease
    Akira Andoh
    Masahiro Kawahara
    Takayuki Imai
    Goichi Tatsumi
    Osamu Inatomi
    Yoichi Kakuta
    Journal of Gastroenterology, 2021, 56 : 881 - 890
  • [27] Thiopurine metabolite testing in inflammatory bowel disease
    Goldberg, R.
    Cunningham, G.
    Moore, G.
    Schulberg, J.
    Brown, S.
    Connell, W.
    Lust, M.
    Kamm, M.
    Bell, S.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S194 - S195
  • [28] Optimizing Thiopurine Therapy in Inflammatory Bowel Disease
    Chevaux, Jean-Baptiste
    Peyrin-Biroulet, Laurent
    Sparrow, Miles P.
    INFLAMMATORY BOWEL DISEASES, 2011, 17 (06) : 1428 - 1435
  • [29] Mercaptopurine and inflammatory bowel disease: the other thiopurine
    Bermejo, Fernando
    Algaba, Alicia
    Lopez-Duran, Sergio
    Guerra, Ivan
    Aicart-Ramos, Marta
    Hernandez-Tejero, Maria
    Garrido, Elena
    de-Lucas, Maria
    Bonillo, Daniel
    Lopez-Sanroman, Antonio
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2017, 109 (01) : 10 - 16
  • [30] Thiopurine treatment in inflammatory bowel disease - Reply
    Schwab, Matthias
    CLINICAL PHARMACOKINETICS, 2007, 46 (09) : 805 - 805
12345